Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger
New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a
Latest news
-
Janssen looks to expand Darzalex in Europe
Additionally, both MorphoSys and Takeda each have their own myeloma drugs in mid-stage testing and Bristol-Myers Squibb and AbbVie are hoping that SLAMF7 targeting Empliciti, in combination with Revlimid,
-
Sanofi's Darzalex rival scores in myeloma trial
In the meantime, additional anti-CD38 competition is looming from the likes of MorphoSys with MOR202 and Takeda with TAK-079, both in mid-stage testing, while J&J and Genmab
-
Morphosys’ Darzalex patent challenge hits a hurdle
In a statement, Morphosys said it was disappointed by the outcome but is considering its options and may launch an appeal. ... Morphosys insists that the court decision has “no bearing” on its patents for MOR202 and its ability to develop the
-
Pfizer abandons antibody for Duchenne
Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
MorphoSys and Galapagos have signed a major new deal with Novartis on their atopic dermatitis candidate MOR106, an IL-17c antibody. ... The deal adds to MorphoSys’ momentum, as it launched its listing on the Nasdaq earlier this year and raised $207
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
-
Pharma deals during June 2014
Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Midweight Brand Planner
-
Up to £50, 000
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
Subscribe to our email news alerts
- Stung by critics, J&J says antidepressant Spravato saves money
- Still no breakthrough on Orkambi talks, MPs want answers
- Curiosity – did it ever really kill the cat?
- Amgen buys Danish partner Nuevolution for $167m
- 90TEN named Best Agency in Continental Europe at PRWeek Global Awards
- Latecomer Lilly preps its IL-23 drug for Crohn’s disease
PMHub
Atlantis Healthcare
Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...
Latest intelligence
- The Exhibition Hall: Past, Present and Future
- As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
- Success breeds success
- This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
- Turning learning into action: The challenge of behaviour change
- ...
Quick links
Infographics
